Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07936708
PHASE1

SA030 Injection in Healthy Participants

Sponsor: Suzhou Siran Biotechnology Co.,Ltd.

View on ClinicalTrials.gov

Summary

This is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single ascending doses of SA030 injection in healthy participants. The planned dose levels include 100 mg, 200 mg, and 400 mg, with 8 eligible participants enrolled in each dose group. All participants receive a single administration of the study drug on Day 1 (D1). In each dose group, the first 2 participants are enrolled as sentinel participants and randomized at a 1:1 ratio to receive either SA030 injection or placebo. After a 5-day safety observation period and favorable safety assessment by the investigator, the remaining 6 participants in the group will be enrolled and randomized at a 5:1 ratio to receive SA030 injection or placebo. For dose escalation, at least 6 out of 8 participants in each dose group must complete the 14-day safety observation period (up to Day 15 \[D15\]). Subsequent dose escalation to the next higher dose level can only be initiated after safety review and approval by the Safety Review Committee (SRC).

Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-dose Escalation Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of SA030 Injection in Healthy Participants

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

24

Start Date

2026-10-16

Completion Date

2027-10-31

Last Updated

2026-11-13

Healthy Volunteers

Yes

Interventions

DRUG

Experimental: 100mg

Single subcutaneous injection of SA030 injection at a dose of 100 mg, one-time administration on Day 1.

DRUG

Experimental: 200mg

Single subcutaneous injection of SA030 injection at a dose of 200 mg, one-time administration on Day 1.

DRUG

Experimental: 400mg

Single subcutaneous injection of SA030 injection at a dose of 400 mg, one-time administration on Day 1.

DRUG

Placebo

Single subcutaneous injection of placebo, one-time administration.

Locations (1)

The First Bethune Hospital of Jilin University

Changchun, Jilin, China